[Cost-effectiveness analysis of delayed-release dimethyl-fumarate in the treatment of relapsing-remitting multiple sclerosis in Italy]
INTRODUCTION: Disease Modifying Therapies (DMTs) have significantly improved clinical conditions of Relapsing Remitting Multiple Sclerosis (RRMS) patients. However, several unmet needs are still relevant in RRMS. Recently, a new therapy, delayed-release dimethyl-fumarate (DMF; also known as gastro-r...
| Autori principali: | , , , , , , |
|---|---|
| Natura: | Articolo |
| Lingua: | English |
| Pubblicazione: |
SEEd Medical Publishers
2016-06-01
|
| Serie: | Farmeconomia: Health Economics and Therapeutic Pathways |
| Soggetti: | |
| Accesso online: | https://journals.seedmedicalpublishers.com/index.php/FE/article/view/1251 |